Technologists
PBCO is proud to present the New Ig Dose Calculator released June 30, 2021.
The new calculator, which matches the one embedded in the Blood Product Request Portal (BPRP), includes the following upgrades and enhancements:
The calculator should not replace sound clinical judgment concerning a patient's unique situation, the aim being to arrive at the lowest possible dose while maintaining clinical efficacy.
If you have any questions or require support please contact the PBCO at
| Recommendations | Dated |
| IVIg Utilization Management Program Recommendations | Jul 2019 |
| Note: The above recommendations are under revision and do not reflect current practice. Provincial panel screening of SCIG for Neurology and Rheumatology conditions took effect on April 1, 2025. Follow links for further information on Immunology recommendations for SID and Neurology recommendations for CNS and PNS. | |
| TMS Ig Request Process | Dated |
| Ig Request Process | Feb 2025 |
| Note: Provincial panel screening of SCIG for Neurology and Rheumatology conditions took effect on April 1, 2025. | |
| Ig Screening Request Form | |
| Outcome Questionnaire | |
| IVIg - PNS | SCIg - PNS |
| IVIg - CNS | SCIg - CNS |
| IVIg - Rheumatology | SCIg - Rheumatology |
|
For all provincially screened adult Rheumatology or Neurology cases, refer to the screening request form and outcome questionnaire as listed above. Please note there are minor differences between each form for IVIg and SCIg, due to differences in dosing. |
|
Immune Globulin (Ig) is an expensive and limited resource. It is prepared by several commercial manufacturers who use plasma derived from donors to produce IVIg and SCIg.
The BC Provincial Blood Coordinating Office (PBCO) operates an Ig Utilization Management Program to ensure that enough IVIg and/or SCIg is available for patients likely to benefit from the treatment. The program incorporates the:
BC Ministry of Health Policy on Health Authority Immune Globulin Utilization Management Directives which requires that requests for IVIG use are screened in hospital Transfusion Medicine Services to ensure that IVIG is used in accordance with the BC IVIg Utilization Management Program Recommendations.
Note that both the Directives and the Recommendations listed above are currently under review to include SCIg. All requests for SCIg should be handled in the same manner as IVIg effective April 1, 2025.
Two specialty panels support centralized screening. Additional information regarding the Rheumatology and Neurology Screening Programs are found on the following corresponding pages:
 |
 |
 |
 |
 |
 |